Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Stomach Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Adenocarcinoma 3Lung Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Neoplasm Metastasis 1Metastatic Gastric Adenocarcinoma 1Liver Neoplasms 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Gastroesophageal Junction Adenocarcinoma 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Cyclophosphamide 149Docetaxel 139Paclitaxel 127Trastuzumab 120Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × Ramucirumab × Clear all
NCT00703326 2021-12-06

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Eli Lilly and Company

Phase 3 Completed
1,144 enrolled 19 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡